CRISPR gene editing created the G795A amino acid which was introduced to microglia derived from human stem cells. Researchers were able to transplant the donor microglia immune cells into humanized rodent models while administering an FDA-approved cancer drug called pexidartinib. The inclusion of the amino acid cause the donated microglia to thrive and resist the drug, while the host microglia died. The findings open the door for new methods of using microglia to treat a range of neurodegenerative disorders.
from Neuroscience News https://ift.tt/Qgw1DFl
from Neuroscience News https://ift.tt/Qgw1DFl
Comments
Post a Comment